In a study of the effect of the glycolytic inhibitors fluoride, iodoacetate, and malonate on a series of more than 100 cases of diverse forms of human cancer, it was found that while objective evidence of tumor inhibition was obtained in cases of acute leukemia, Hodgkin's disease, and lymphosarcoma, this was not the case in patients with carcinoma of the colon, fundus uteri, ovary, pancreas, rectum, or in chronic leukemia, melanoma, chorionepithelioma testis, or with squamous cell cancers of the cheek and pharynx. Some responses of a less definitive nature were elicited in cancers of the breast, adrenal cortex, cervix, lung, stomach, and testes. These observations suggest that while certain cancer types behave as if they were particularly dependent on glycolytic mechanisms for their energy requirements, this is certainly not the case for all or even the majority of them. Further, even in those cases which may exhibit definite regression under glycolytic inhibitor therapy, an insensitivity develops and reactivation of the process occurs. These findings are discussed in relation to in vitro observations of cancer metabolism.


This work was supported by the Leukemia Research Foundation, Inc.

This content is only available via PDF.